
    
      AB680 will be administered as single and multiple intravenous doses to the healthy
      volunteers. In each group of 8 participants, 6 will receive AB680 and 2 will receive matching
      placebo.

      The participants will be closely observed to monitor the general tolerability of AB680.
    
  